FDA Grants CytoDyn Fast Track Designation for Leronlimab (PRO 140) in metastatic Triple-Negative Breast Cancer, an Unmet Medical Need

Stock Information for CytoDyn Inc

Loading

Please wait while we load your information from QuoteMedia.